Press Releases

07.19.2016

Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13®

07.13.2016

Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis

07.12.2016

Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49

07.08.2016

Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT® (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma

07.06.2016

Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

07.01.2016

BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.

06.28.2016

Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results

06.27.2016

Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

06.24.2016

Pfizer Completes Acquisition of Anacor

06.21.2016

Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts

06.16.2016

Help Pfizer Change The Future Of Healthy Aging

06.16.2016

Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts